#5 - Medtronic (NYSE:MDT)
Every investor should have some exposure in the healthcare sector. The aging of America continues to be as investable theme as much in 2022 as it was in 1992. And in part because of its dividend aristocrat status, Medtronic (NYSE:MDT) is an appealing option.
Medtronic gives investors exposure to several areas including medical devices, surgical tools and devices, neuroscience, and diabetes treatment. This diversified product offering is one reason the company is attractive to investors.
Another reason is the dividend which the company has increased in each of the last 46 years. It currently pays out $2.72 per share on an annual basis and has a dividend yield of just over 3% which is more than double the sector average. Plus, the company has posted an annualized three-year dividend growth of 8%.
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Read More - Current Price
- $85.33
- Consensus Rating
- Hold
- Ratings Breakdown
- 7 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $95.00 (11.3% Upside)
